Study published in PLoS Pathogens suggests new target for treatment and the eventual cure of HIV/AIDS
UNC faculty members Robert Dodge, PhD, RN, ANP, Jacqueline Gibson, PA-C, Victoria Mobley, MD, Esther Metiko, FNP and Ann Dennis, MD, work at the Raleigh-based clinic, which has over 900 patients.
The Institute for Global Health & Infectious Diseases is co-hosting a delegation from the White House Office of National AIDS Policy, including ONAP director Grant Colfax. Part of their visit will involve a U.S. National HIV/AIDS Implementation Meeting in Chapel Hill on February 21, 2013.
Myron Cohen, MD, J. Herbert Bate Distinguished Professor of Medicine, Microbiology and Immunology, and Epidemiology, was featured in the Sunday, Dec. 30 issue of the N&O along with Robert J. Lefkowitz, MD, also a "Tar Heel of Year" for 2012.
The consortium, which involves four partnering institutions, will support early-career scientists and clinicians during a yearlong research fellowship at 17 sites in 13 countries in Africa, Asia, and South America.
Election to the IOM is considered one of the highest honors in the fields of health and medicine and recognizes individuals who have demonstrated outstanding professional achievement and commitment to service.
ID Conference: “Lessons from Botswana: Prevention and Treatment in the World’s Worst Epidemic of HIV/AIDS”
The presenter is Max Essex, DVM, PhD, Lasker Professor of Health Sciences at Harvard University, Chair of the Harvard School of Public Health AIDS Initiative, and Chair of the Botswana–Harvard AIDS Institute in Gaborone, Botswana.
The Collaboratory of AIDS Researchers for Eradication, or CARE, a multi-institutional research team led by David Margolis, MD, professor of medicine at the UNC School of Medicine, has been awarded a $2 million supplemental grant from the National Institutes of Health to conduct expanded analysis of resting CD4+ T-cells of people infected with HIV.
Researchers from the University of North Carolina at Chapel Hill have published pioneering research showing that a drug used to treat certain types of lymphoma was able to dislodge hidden virus in patients receiving treatment for HIV.
Research from every corner of the UNC campus will be represented at the International AIDS Conference, to be held July 22-27 in Washington, D.C.
Cohen co-authors "Pre-exposure Prophylaxis for HIV - Where Do We Go from Here?" in the New England Journal of Medicine
Myron Cohen, MD, collaborated with Lindsay Bahen, MD, from Brigham and Women's Hospital in Boston, Mass., for this editorial that was published in the New England Journal of Medicine.
New research from the University of North Carolina School of Medicine demonstrates that breast milk in a humanized mouse model has a strong virus killing effect and protects against oral transmission of HIV.
A new study may help clarify why some people infected with HIV are better able to control the virus. It may also pinpoint a target for treatment during early HIV infection aimed at increasing the supply of certain immune cells in the gut.
A team of researchers led by the University of North Carolina School of Medicine has demonstrated that latency develops soon after infection and slows when antiretroviral therapy is given.
New research finds that early weaning – stopping breastfeeding before six months – is of little, if any, protective value against HIV transmission nor is it safe for infant survival.
Cohen’s study, HIV Prevention Trials Network 052, showed that treating people with HIV with antiretroviral therapy renders them virtually non-contagious, reducing sexual transmission by 96 percent.
Learn more about the HPTN study, called the "Breakthrough of the Year," in this Q&A about the the process of discovery with Dr. Mike Cohen, Director of the UNC Institute for Global Health and Infectious Diseases.
Dr. Myron Cohen won the Lifetime Achievement Award, Dr. Norman Sharpless, the Innovator/Researcher award, and Dr. Adam Zanation the "Rising Star" award.
UNC-led team offers clinical, research agenda
This study is the first to demonstrate that the biological mechanism that keeps the HIV virus hidden and unreachable by current antiviral therapies can be targeted and interrupted in humans, providing new hope for a strategy to eradicate HIV completely.